Hodgkin lymphoma

October 27, 2016October 27, 2016

New Report Supports Opdivo for Relapsed Hodgkin’s Lymphoma Patients

News

Bristol-Myers Squibb recently presented data supporting the use of Opdivo (nivolumab) in a subgroup of patients with classical Hodgkin’s lymphoma who had undergone a prior stem cell transplant and treatment with ... Read more

October 11, 2016October 11, 2016

Fatigue Seen as Common Problem in Hodgkin’s Lymphoma Survivors

News

Persistent and debilitating fatigue is a common problem for survivors of Hodgkin lymphoma, regardless of their disease stage or type of treatment, researchers in Germany reported. The study, “Cancer-related fatigue ... Read more

September 16, 2016September 16, 2016

Hodgkin’s Lymphoma Patients Respond Well in Study of Triple Combo Therapy with Adcetris

News

Patients with early stage, unfavorable risk classical Hodgkin’s lymphoma who are treated with Adcetris (brentuximab vedotin) and chemotherapy, followed by radiation therapy, are more likely to achieve complete responses than those ... Read more

September 8, 2016

Survivors of Childhood Hodgkin’s Lymphoma Show Increased Likelihood of Cardiovascular Events as Adults

News

The vast majority of children and adolescents treated for Hodgkin’s lymphoma will survive into adulthood. But according to a recent study developed at St. Jude Children’s Research Hospital, adult survivors of ... Read more

August 8, 2016August 8, 2016

Young Hodgkin’s Lymphoma Patients at Twice the Risk of Heart Disease in Adulthood

News

A new statistical method created by investigators to quantify the total cardiovascular burden of adults who had Hodgkin lymphoma (HL) as children found that these pediatric HL survivors had more and more serious cardiovascular problems by age 50 than others their age without this type of childhood ... Read more

July 7, 2016July 7, 2016

European Commission Approves Adcetris as Consolidation Treatment for Post-transplant Hodgkin’s Lymphoma Patients

News

The European Commission has approved Adcetris (brentuximab vedotin) for the treatment of adults with CD30-positive Hodgkin’s lymphoma at increased risk of relapse or progression after autologous stem cell transplant (ASCT), ... Read more

June 21, 2016June 21, 2016

HIV-Related Lymphoma: Autologous Hematopoietic Cell Transplant Recommended as Standard of Care

News

Patients with HIV-associated lymphoma who receive autologous hematopoietic cell transplantation (AHCT) have similar survival rates and complication rates than non-HIV lymphoma patients, suggesting that AHCT should be added as standard of ... Read more

June 15, 2016

Patient Testimony: Life After Immunotherapy for Lymphoma

The most common courses of treatment for Hodgkin lymphoma are chemotherapy, radiation therapy, or a combination of the two. However, immunotherapy is also an option, and in the case of ... Read more

June 9, 2016June 9, 2016

Pedriatric Hodgkin Lymphoma Patients Who Gain Body Fat During Treatment May Be at Higher Risk of Relapsing

News

Increase in body fat in pediatric Hodgkin lymphoma patients may be linked to disease relapse, according to the study “Visceral fat and muscle changes during 6-week chemotherapy in pediatric Hodgkin ... Read more

May 31, 2016May 31, 2016

CHMP Favors Approval of Adcetris (brentuximab vedotin) to Treat Post-Transplant Hodgkin Lymphoma

News

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the present provisional approval of Takeda Pharmaceutical’s Adcetris (brentuximab ... Read more